During stock investing, having a list of the top undervalued stocks can offer lucrative opportunities for value growth and portfolio stability. Here are three stocks whose intrinsic value exceeds their current market price, promising potential gains as the market corrects itself. The fundamentals that drive these stocks are operational efficiency, market penetration and innovation. These elements support these companies’ ability to capitalize on the inefficiencies of the restaurant, pharmaceutical and footw ...

Core Viewpoint - In the latter half of 2024, three dividend stocks—Johnson & Johnson, Procter & Gamble, and Coca-Cola—are highlighted as strong investment opportunities due to their resilience, consistent performance, and reliable dividend distributions [1][5]. Company Summaries Johnson & Johnson - Johnson & Johnson (NYSE: JNJ) is recognized for its diversified portfolio in healthcare, offering a dividend yield of approximately 2.8% [2]. - The stock has experienced bearish sentiments in 2024, with a year-to-date (YTD) decline of over 9%, closing at $145 on July 8 [2]. Procter & Gamble - Procter & Gamble Co. (NYSE: PG) leads in consumer goods with a dividend yield around 2.5% [3]. - The company has shown positive growth in 2024, with the stock surging over 11% YTD, valued at $166.52 [3]. Coca-Cola - Coca-Cola Company (NYSE: KO) offers a dividend yield of approximately 3.1%, making it attractive for investors [4]. - The stock has registered positive gains in 2024, increasing over 5% with a share price of $62 at the time of reporting [4]. Investment Insights - All three companies have a long history of paying dividends, suggesting a lower risk of dividend cuts compared to newer firms [6]. - Each company has consistently increased their dividends over time, appealing to income-oriented investors [6]. - The companies operate in defensive sectors (healthcare and consumer staples), which tend to perform well during economic downturns, providing stability to portfolios [6].

Core Viewpoint - Johnson & Johnson has experienced a decline of approximately 9% over the last 10 months, underperforming compared to the S&P 500, which increased by 23% in the same period. The stock is now at its lowest valuation in at least 35 years, prompting a reevaluation of its investment potential [1][2]. Valuation Multiples - The current price-earnings (P/E) ratio for Johnson & Johnson is 9.7, the lowest in the last five years and potentially the lowest in 35 years, indicating undervaluation [2]. - The price-free-cash-flow (P/FCF) ratio stands at 20, slightly below the five-year average of 22.44, suggesting a hold rather than a buy at this point [3]. Quarterly Results - For Q1 2024, Johnson & Johnson reported sales of $21,383 million, a 2.3% increase year-over-year from $20,894 million in Q1 2023. Diluted earnings per share improved from a loss of $0.19 to $2.20 [4]. - Adjusted earnings per share rose by 12.4% year-over-year, from $2.41 in Q1 2023 to $2.71 in Q1 2024 [4]. Guidance - Management expects adjusted operating sales to grow between 5.5% and 6.0%, with reported sales projected around $88 billion, indicating about 5% top-line growth. Adjusted earnings per share are anticipated to be between $10.57 and $10.72 [5][6]. Segment Results - The MedTech segment reported $7,821 million in revenue, reflecting a 4.5% year-over-year growth, impacted by fewer selling days [8]. - The Innovative Medicines segment generated $13,562 million in revenue, with a 1.1% year-over-year growth. Excluding the COVID-19 vaccine impact, operational sales grew by 8.3% [9][10]. Growth Strategies - Johnson & Johnson has been engaging in share buybacks, reducing outstanding shares from approximately 3 billion to 2.43 billion over the last 20 years, contributing about 2% annually to the bottom line [11][12]. - The company has made significant acquisitions, including Shockwave Medical for $13.1 billion and Proteologix for $850 million, aimed at enhancing its position in cardiovascular intervention and oncology [12]. Litigation Risks - Johnson & Johnson faces over 50,000 lawsuits related to its talc products, with a proposed $6.5 billion settlement to resolve most claims. The company has set aside $13.7 billion in reserves for these legal challenges [13]. Intrinsic Value Calculation - Based on a free cash flow of $18.23 billion and a conservative growth estimate of 6%, the intrinsic value of Johnson & Johnson is calculated at $187.55, indicating the stock is undervalued at its current trading price of $146 [15][16]. Upcoming Earnings - Analysts have mixed sentiments regarding the upcoming Q2 earnings, with more revenue revisions upward but more downward revisions for earnings per share, indicating a bearish outlook [17]. Conclusion - Johnson & Johnson is considered a "Buy" for long-term stability and consistent dividend payments, although short-to-mid-term risks of lower stock prices exist. The company is viewed as a bond-like investment, providing steady returns [18].

Core Insights - CARVYKTI® is the first and only BCMA-targeted CAR-T cell therapy approved by the U.S. FDA for treating multiple myeloma patients who have had at least one prior line of therapy [1] - Johnson & Johnson announced positive results from the Phase 3 CARTITUDE-4 study, showing significant improvement in overall survival for patients treated with CARVYKTI® compared to standard therapies [1][2] - The CARTITUDE-4 study is the first randomized Phase 3 trial evaluating CARVYKTI® against standard care treatments for relapsed or lenalidomide-refractory multiple myeloma [3] Company Overview - Johnson & Johnson is focused on innovative medicine and aims to improve outcomes for patients with multiple myeloma through differentiated therapies [2][37] - The company has a collaboration with Legend Biotech USA, Inc. for the development and commercialization of CARVYKTI® [5] Product Information - CARVYKTI® (ciltacabtagene autoleucel) received FDA approval in February 2022 and was later approved for a broader indication in April 2024 [4] - The therapy is a genetically modified autologous T-cell immunotherapy targeting BCMA, which is primarily expressed on malignant multiple myeloma B-lineage cells [5] - The primary endpoint of the CARTITUDE-4 study is progression-free survival, with secondary endpoints including overall survival and overall response rate [3] Market Context - Multiple myeloma is the third most common blood cancer globally, with over 35,000 new diagnoses expected in the U.S. in 2024 [6][7] - The disease remains incurable, highlighting the need for effective treatment options like CARVYKTI® [6][7] Clinical Data - The CARTITUDE-4 study demonstrated a statistically significant improvement in overall survival for CARVYKTI® compared to standard therapies [1][2] - Safety data from the study were consistent with the approved label, indicating manageable adverse effects [1][2] Regulatory Developments - Updated results from the CARTITUDE-4 study will be presented at medical meetings and submitted to regulatory authorities worldwide [2] - CARVYKTI® has received approvals from both the FDA and the European Medicines Agency for specific patient populations [4]

Income-seeking investors can find plenty of opportunities in any market environment.Dividend stocks offer a great way to add cash to your portfolio and help you compound your overall returns with time. Whether you use that dividend money to add to your portfolio or cash it out, these types of stocks can help you diversify the types of businesses you own shares in.When it comes to investing in dividend stocks, you need to make sure the companies you buy have a strong underlying business and balance sheet tha ...

Core Insights - Johnson & Johnson announced positive results from the Phase 3 Vivacity-MG3 study for nipocalimab in patients with generalized myasthenia gravis (gMG), demonstrating superiority over placebo in improving daily living activities [1][2][3] Study Results - Patients receiving nipocalimab plus standard of care (SOC) showed a mean improvement of 4.70 points on the MG-ADL score compared to a 3.25 point improvement in the placebo group, with a statistically significant difference (P=0.002) [2][4] - The study enrolled 199 patients, with 153 being antibody positive, and was designed to measure sustained efficacy and safety over 24 weeks [6][7] - Key secondary endpoints, including improvement in muscle strength and function measured by QMG, were also significantly better in the nipocalimab group (P<0.001) [2][4] Safety Profile - The safety and tolerability of nipocalimab were consistent with previous studies, showing similar rates of adverse events compared to the placebo group [3][4] Treatment Need - There is a significant unmet need for new treatment options in gMG, a chronic, autoantibody-driven disease affecting approximately 700,000 people worldwide [5][6] - Current SOC therapies may not be sufficient for all patients, highlighting the importance of developing new treatments like nipocalimab [5][6] Regulatory Designations - Nipocalimab has received several key designations from the FDA and EMA, including Fast Track and Orphan Drug status for various conditions, indicating its potential significance in treating gMG and other autoantibody-related diseases [7][8]

Core Viewpoint - Johnson & Johnson is focusing on growth through its medical devices and innovative medicines segments after spinning off its consumer health business, but investor confidence remains low due to ongoing legal challenges [1][2]. Business Performance - The company reported $21.4 billion in sales for the first three months of 2024, with a 2.3% increase in sales, which rises to 3.9% when excluding foreign exchange impacts [4]. - Management projects an annual operational growth rate of 5% to 7% from 2025 to 2030, expecting over 10 assets to generate at least $5 billion in peak annual sales [5]. Legal Challenges - Johnson & Johnson is facing significant legal battles related to its talc products, with ongoing lawsuits claiming they caused ovarian cancer. The company is attempting a selective bankruptcy filing to manage these liabilities [2][3]. - The current settlement plan of $6.5 billion does not include claims related to mesothelioma, focusing instead on ovarian cancer cases, which constitute the majority of lawsuits [3]. Investment Considerations - The stock is currently trading at a modest 14 times its estimated future earnings and offers a dividend yield of 3.3%, making it potentially appealing for value investors [6]. - Despite the potential for modest growth, the ongoing legal issues may lead to substantial litigation expenses, prompting some investors to consider alternative options [7].

The latest trading session saw Johnson & Johnson (JNJ) ending at $147.19, denoting a -1.29% adjustment from its last day's close. This move lagged the S&P 500's daily gain of 0.09%. Meanwhile, the Dow experienced a drop of 0.1%, and the technology-dominated Nasdaq saw an increase of 0.16%.Prior to today's trading, shares of the world's biggest maker of health care products had gained 1.46% over the past month. This has lagged the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time.The ...

J&J is the textbook blue chip stock -- but it's not for everyone.Investing comes in many flavors, so there isn't a right or wrong approach: You should do what's best for you. That applies even to dividend investing. For some, dividend investing means maximizing immediate income, even if it requires sacrificing some growth and long-term upside; for others, it's the opposite.Healthcare juggernaut Johnson & Johnson (JNJ 0.25%) is a hallowed name in the dividend community, both for its brand recognition and for ...

blackred FOMO (fear of missing out) is hard to ignore when it comes to buying stocks in today's market, especially when influencers post headline-making comments about meme stocks like GameStop (GME) or when expensive stocks just keep going up, as in the case of Nvidia (NVDA), whose market cap just surpassed that of Microsoft (MSFT) to become the world's most valuable company. I'm not bothered, however, by not participating in the aforementioned stock rallies as I'm happy to layer into discounted divide ...